menu
    • menu
    [{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"Tregs migration","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Macleods Pharmaceuticals Limited \/ Macleods Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Macleods Pharmaceuticals Limited \/ Macleods Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Macleods Pharmaceuticals Limited

    Menu

    Macleods Pharmaceuticals Limited

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Macleods Pharmaceuticals Limited

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Macleods Pharmaceuticals Limited

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : CytoDyn

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Ac...

                            Details : Leronlimab is a viral-entry inhibitor in HIV/AIDS. This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance.

                            Brand Name : PRO 140

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : CytoDyn

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth